Allysia Matthews, PhD
Associate Research ScientistCards
About
Research
Publications
2026
High-Grade Immune-Related Adverse Events Resulting from Immune Checkpoint Inhibitor Treatment: Evaluation of Diagnostics and Outcomes in Admitted Patients
Legakis L, Naagendran M, Matthews A, Morris J, Davies M, Prsic E, Price C. High-Grade Immune-Related Adverse Events Resulting from Immune Checkpoint Inhibitor Treatment: Evaluation of Diagnostics and Outcomes in Admitted Patients. Supportive Care In Cancer 2026, 34: 222. PMID: 41711961, DOI: 10.1007/s00520-026-10448-w.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsSevere immune-related adverse eventsLength of stayToxicity gradeCytokine signatureAdverse eventsAssociated with immune-related adverse eventsHigh-grade immune-related adverse eventsDiagnostic evaluationImmune checkpoint inhibitor treatmentMedian time to toxicityIL-6Checkpoint inhibitor treatmentHigh-grade toxicityPurposeImmune checkpoint inhibitorsRetrospective case reviewInterleukin (IL)-10ICI rechallengeCheckpoint inhibitorsICI initiationCorticosteroid treatmentPrimary cancerElevated CRPElevated biomarkersClinical outcomes